Fibrogen Company Profile

08:51 EDT 17th March 2018 | BioPortfolio

Extracellular matrix biology to discover and develop innovative therapies for fibroproliferative disorders - organ fibrosis, tissue repair and regeneration.


225 Gateway Boulevard
South San Francisco
United States of America


Phone: 415 635 1500
Fax: 650 866 7204

News Articles [19 Associated News Articles listed on BioPortfolio]

FibroGen Says CFDA Accepts Novel Anemia NDA for Review

FibroGen, a US-China biopharma, reported the CFDA has accepted an NDA to review its novel anemia treatment for China approval. Roxadustat is a first-in-class oral treatment for anemia in patients unde...

FDA fast-tracks review of FibroGen's pancreatic cancer therapy

FibroGen's pamrevlumab, which is indicated to treat patients with locally advanced, unresectable pancreatic cancer, was given -More- 

Astrazeneca und Fibrogen: Die China-Sonderstory des Jahres

Für die britisch-schwedische Astrazeneca steht zusammen mit dem AKTIONÄR-Hot-Stock Fibrogen in China demnächst die Zulassungsentscheidung zum Anämie-Mittel Roxadustat auf der Agenda. Das Duo könn...

CFDA reviewing roxadustat, FibroGen gets $15M payday

FibroGen Reports Third Quarter 2017 Financial Results

Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results ReportedConference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time...

FibroGen's (FGEN) CEO Tom Neff on Q3 2017 Results - Earnings Call Transcript

FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017

SAN FRANCISCO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the third quart...

FibroGen's (FGEN) CEO Tom Neff on Q4 2017 Results - Earnings Call Transcript

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Single compassionate use subject is an 83 year old woman with a history of lymph node positive breast cancer and recently diagnosed pancreatic cancer in May. With an Eastern Cooperative On...

The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease

- Patients with Motor Neurone Disease (MND) admitted to Lane Fox Unit /Royal Brompton Hospital and/or reviewed in Lane Fox Unit /Royal Brompton Hospital clinics and/or outreach ...

Companies [2 Associated Companies listed on BioPortfolio]

FibroGen, Inc.

FibroGen, Inc. is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible ...


Extracellular matrix biology to discover and develop innovative therapies for fibroproliferative disorders - organ fibrosis, tissue repair and regeneration.

More Information about "Fibrogen" on BioPortfolio

We have published hundreds of Fibrogen news stories on BioPortfolio along with dozens of Fibrogen Clinical Trials and PubMed Articles about Fibrogen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fibrogen Companies in our database. You can also find out about relevant Fibrogen Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record